Ansastrozole

Phase 3Small molecule

Novartis

Ansastrozole is one of 30 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Early Breast CancerRecruiting

Breast CancerPhase 3

Active, not recruiting

Early Breast CancerPhase 3

Recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Ansastrozole

Novartis

Phase 3

1 3

Gemzar

GGynecologic Oncology Group

Preclinical

22 4

DATROWAY

Daiichi Sankyo

Preclinical

4 5

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 6

Adenocard

Astellas

Preclinical

1 7

Lexiscan

Astellas

Preclinical

1 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 9

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 10

Vfend

PPrism Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 3Recruiting

Early Breast Cancer

NCT05827081

Clinical

Trials by Indication[1]

Early Breast Cancer1 trial

A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)

Recruiting· Novartis logo

Novartis·Phase 3·NCT05827081·1,400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ansastrozole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ansastrozole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ansastrozole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Ansastrozole

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Early Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News